Differences in biomarkers and molecular pathways according to age for patients with HFrEF.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
29 08 2021
Historique:
received: 29 05 2020
revised: 21 08 2020
accepted: 17 09 2020
pubmed: 2 10 2020
medline: 25 2 2022
entrez: 1 10 2020
Statut: ppublish

Résumé

Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse prognosis and less often receive guideline-recommended therapies. We aim to better understand the underlying pathophysiological processes associated with ageing in HFrEF potentially leading to targeted therapies in this vulnerable population. From a panel of 363 cardiovascular biomarkers available in 1611 patients with HFrEF in the BIOSTAT-CHF index cohort and cross-validated in 823 patients in the BIOSTAT-CHF validation cohort, we tested which biomarkers were dysregulated in patients aged >75 vs. <65 years. Second, pathway overrepresentation analyses were performed to identify biological pathways linked to higher plasma concentrations of biomarkers in elderly vs. younger patients. After adjustment, multiple test correction [false discovery rate (FDR) 1%], and cross-validation, 27/363 biomarkers were associated with older age, 22 positively and 5 negatively. The biomarkers that were positively associated with older age were associated with tumour cell regulation, extra-cellular matrix organization, and inflammatory processes, whereas biomarkers negatively associated with older age were associated with pathways that may point to cell proliferation and tumourigenesis. Among the 27 biomarkers, WFDC2 (WAP four-disulphide core domain protein 2)-that broadly functions as a protease inhibitor-was associated with older age and had the strongest association with all outcomes. No protein-by-sex interaction was observed. In elderly HFrEF patients, pathways associated with extra-cellular matrix organization, inflammatory processes, and tumour cell regulation were activated, while pathways associated with tumour proliferation functions were down-regulated. These findings may help in a better understanding of the ageing processes in HFrEF and identify potential therapeutic targets.

Identifiants

pubmed: 33002110
pii: 5917017
doi: 10.1093/cvr/cvaa279
doi:

Substances chimiques

Biomarkers 0
Proteome 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2228-2236

Subventions

Organisme : European Commission
ID : FP7-242209-BIOSTAT-CHF
Organisme : Roche Diagnostics
Organisme : French PIA project 'Lorraine Université d'Excellence' GEENAGE
ID : ANR-15-IDEX-04-LUE
Organisme : European Research Council (ERC
ID : CoG 818715

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

João Pedro Ferreira (JP)

Université de Lorraine, Inserm, Centre d'Investigation Clinique - Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy 54500, France.

Wouter Ouwerkerk (W)

National Heart Centre Singapore, Hospital Drive, Singapore 169659, Singapore.
Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.

Bernadet T Santema (BT)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Dirk J van Veldhuisen (DJ)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Chim C Lang (CC)

Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Leong L Ng (LL)

Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, NIHR Leicester Biomedical Research Centre, Leicester, UK.

Stefan D Anker (SD)

Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Kenneth Dickstein (K)

Cardiology Division, Stavanger University Hospital, Postboks 8100, 4068 Stavanger, Norway.

Marco Metra (M)

Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

John G F Cleland (JGF)

Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

Samani J Nilesh (SJ)

Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, NIHR Leicester Biomedical Research Centre, Leicester, UK.

Gerasimos Filippatos (G)

National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.

Joseph-Pierre Aboumsallem (JP)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Rudolf A de Boer (RA)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Sylwia Figarska (S)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Iziah E Sama (IE)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Adriaan A Voors (AA)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Faiez Zannad (F)

Université de Lorraine, Inserm, Centre d'Investigation Clinique - Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), 4 rue du Morvan, Nancy 54500, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH